Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIR 19 in Mild COVID-19 Outpatients
NCT05783206Phase 3Completed
- Start
- Feb 2022
- Primary completion
- Jul 2023
- Modality
- Conjugated siRNA, Peptides, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 3 trial of Mir-19 in coronavirus disease 2019 (COVID-19). Started Feb 2022; status: completed.
02
Drugs
Mir-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05783206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783206.